[Effect of KP-136 on allergic paw edema in the rat].
The pharmacological properties of KP-136, an inhibitor of type I allergy, were studied in rat paw models. In four allergic responses, three of the immediate type and one delayed type, KP-136 (p.o.) produced potent inhibitions on the mast cell-mediated type I allergy (ID30: 1.0 mg/kg) and the neutrophil-infiltrated passive Arthus reaction (ID30: 1.6 mg/kg). In addition, KP-136 (10 mg/kg, 50 mg/kg, p.o.) inhibited the injury of bone tissues in rat adjuvant arthritis, confirming that it was effective on the allergic inflammation with tissue injury. Although KP-136 was a weak inhibitor of carrageenin-induced paw edema, prostaglandin synthesis and complement-mediated hemolysis, the compound inhibited the release of lysosomal enzymes such as lysozyme and beta-glucuronidase in the passive Arthus reaction, suggesting the blockage of inflammatory mediator release for its mode of action.
Hiyama
Y
Y
Central Research Laboratory, Kaken Pharmaceutical Co. Ltd., Kyoto, Japan.
Kuriyama
K
K
D000818:Animals; D001168:Arthritis / Q000188:drug therapy*; D001169:Arthritis, Experimental / Q000188:drug therapy*; D001183:Arthus Reaction / Q000188:drug therapy*; D001393:Azoles / Q000627:therapeutic use*; D002351:Carrageenan; D002867:Chromones / Q000494:pharmacology / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy*; D006461:Hemolysis / Q000187:drug effects; D006968:Hypersensitivity, Delayed / Q000188:drug therapy; D006969:Hypersensitivity, Immediate / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D011453:Prostaglandins / Q000096:biosynthesis; D011817:Rabbits; D051381:Rats; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
D001393:Azoles; D002867:Chromones; D007166:Immunosuppressive Agents; D011453:Prostaglandins; D013777:Tetrazoles; C053066:KP 136; D002351:Carrageenan